| Schneeflocken-Punktzahl | |
|---|---|
| Bewertung | 4/6 |
| Künftiges Wachstum | 1/6 |
| Vergangene Leistung | 2/6 |
| Finanzielle Gesundheit | 4/6 |
| Dividenden | 0/6 |
Community Narratives
Create a narrativeNarratives bring a range of perspectives from our community.
WA
Based on Analyst Price Targets
Cost Efficiency And Digital Strategy Propel Earnings Amidst Pharma Industry Challenges
US$224.07
FV
8.2% undervalued intrinsic discount4.14%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
13 days agoauthor updated this narrative
Charles River Laboratories International, Inc. Wettbewerber
Preisentwicklung & Leistung
| Historische Aktienkurse | |
|---|---|
| Aktueller Aktienkurs | US$205.79 |
| 52-Wochen-Hoch | US$275.00 |
| 52-Wochen-Tief | US$161.65 |
| Beta | 1.36 |
| 11 Monat Veränderung | 0.25% |
| 3 Monate Veränderung | -1.93% |
| 1 Jahr Veränderung | 3.09% |
| 33 Jahre Veränderung | -55.10% |
| 5 Jahre Veränderung | 55.17% |
| Veränderung seit IPO | 835.41% |
Aktuelle Nachrichten und Updates
Why Charles River Laboratories International, Inc. (NYSE:CRL) Could Be Worth Watching
Sep 10
US$227: That's What Analysts Think Charles River Laboratories International, Inc. (NYSE:CRL) Is Worth After Its Latest Results
Aug 10Charles River Laboratories: Q2, Cost Structure Streamlining (Rating Upgrade)
Aug 10Recent updates
Why Charles River Laboratories International, Inc. (NYSE:CRL) Could Be Worth Watching
Sep 10US$227: That's What Analysts Think Charles River Laboratories International, Inc. (NYSE:CRL) Is Worth After Its Latest Results
Aug 10Charles River Laboratories: Q2, Cost Structure Streamlining (Rating Upgrade)
Aug 10Charles River Laboratories International (NYSE:CRL) Takes On Some Risk With Its Use Of Debt
Jul 26Risks To Shareholder Returns Are Elevated At These Prices For Charles River Laboratories International, Inc. (NYSE:CRL)
Jul 11Charles River Laboratories: Fair Valuation Against Fundamentals
May 31What Is Charles River Laboratories International, Inc.'s (NYSE:CRL) Share Price Doing?
May 25Is Charles River Laboratories International, Inc. (NYSE:CRL) Trading At A 30% Discount?
Apr 27Charles River Laboratories International, Inc.'s (NYSE:CRL) Price Is Out Of Tune With Earnings
Apr 11Charles River Laboratories International (NYSE:CRL) Has A Pretty Healthy Balance Sheet
Mar 27Charles River Laboratories International (NYSE:CRL) Strong Profits May Be Masking Some Underlying Issues
Feb 21Charles River Laboratories: Weak Biopharma Spending Is Transitory; Initiate With 'Hold'
Feb 16Is It Time To Consider Buying Charles River Laboratories International, Inc. (NYSE:CRL)?
Jan 17Charles River Laboratories International, Inc.'s (NYSE:CRL) Share Price Not Quite Adding Up
Jan 02Charles River Laboratories International (NYSE:CRL) Ticks All The Boxes When It Comes To Earnings Growth
Dec 17Charles River Laboratories: Mr. Market Went From Overvaluation To Undervaluation
Nov 26Is Charles River Laboratories International, Inc. (NYSE:CRL) Trading At A 29% Discount?
Nov 12Charles River: Q3 Points To Ongoing Deterioration
Nov 09Charles River Laboratories International (NYSE:CRL) Has A Somewhat Strained Balance Sheet
Oct 27At US$197, Is Charles River Laboratories International, Inc. (NYSE:CRL) Worth Looking At Closely?
Oct 12Charles River Laboratories: Diving Into The Lab (Rating Upgrade)
Oct 06Is Charles River Laboratories International, Inc. (NYSE:CRL) Trading At A 27% Discount?
Aug 10Charles River Laboratories: Very Attractive After The Pullback
Jul 26Does Charles River Laboratories International (NYSE:CRL) Deserve A Spot On Your Watchlist?
Jul 22Charles River Laboratories International (NYSE:CRL) Seems To Use Debt Quite Sensibly
Jul 03When Should You Buy Charles River Laboratories International, Inc. (NYSE:CRL)?
Jun 19A Look At The Intrinsic Value Of Charles River Laboratories International, Inc. (NYSE:CRL)
May 01Should You Be Adding Charles River Laboratories International (NYSE:CRL) To Your Watchlist Today?
Apr 16These 4 Measures Indicate That Charles River Laboratories International (NYSE:CRL) Is Using Debt Reasonably Well
Apr 02Is Charles River Laboratories International, Inc. (NYSE:CRL) Potentially Undervalued?
Mar 19Charles River gains as Guggenheim upgrades despite post-earnings selloff
Feb 23Aktionärsrenditen
| CRL | US Life Sciences | US Markt | |
|---|---|---|---|
| 7D | 3.6% | 0.8% | 1.6% |
| 1Y | 3.1% | 12.5% | 30.5% |
Rendite im Vergleich zur Industrie: CRL unter dem Niveau der Branche US Life Sciences , die im vergangenen Jahr eine Rendite von 0.9% erzielte.
Rendite vs. Markt: CRL hinter dem Markt US zurück, der im vergangenen Jahr eine Rendite von 18.6 erzielte.
Preisvolatilität
| CRL volatility | |
|---|---|
| CRL Average Weekly Movement | 5.8% |
| Life Sciences Industry Average Movement | 8.9% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 15.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stabiler Aktienkurs: CRL hat in den letzten 3 Monaten keine nennenswerten Preisschwankungen aufgewiesen.
Volatilität im Zeitverlauf: CRLDie wöchentliche Volatilität (4%) ist im vergangenen Jahr stabil geblieben.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 1947 | 21,100 | Jim Foster | www.criver.com |
Charles River Laboratories International, Inc. bietet Dienstleistungen in den Bereichen Arzneimittelforschung, nicht-klinische Entwicklung und Sicherheitstests in den Vereinigten Staaten, Europa, Kanada, im asiatisch-pazifischen Raum und international an. Das Unternehmen ist in drei Segmenten tätig: Research Models and Services (RMS), Discovery and Safety Assessment (DSA) und Manufacturing Solutions (Manufacturing). Das RMS-Segment produziert und verkauft Nagetiere sowie speziell gezüchtete Ratten und Mäuse für den Einsatz in der Forschung.
Charles River Laboratories International, Inc.'s Grundlagenzusammenfassung
| CRL grundlegende Statistiken | |
|---|---|
| Marktanteil | US$10.63b |
| Gewinn(TTM) | US$431.79m |
| Umsatz(TTM) | US$4.08b |
24.6x
Kurs-Gewinn-Verhältnis2.6x
Kurs-Umsatz-VerhältnisIst CRL zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| CRL Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | US$4.08b |
| Kosten der Einnahmen | US$2.61b |
| Bruttogewinn | US$1.47b |
| Sonstige Ausgaben | US$1.04b |
| Umsatz | US$431.79m |
Zuletzt gemeldete Gewinne
Jun 29, 2024
Datum des nächsten Gewinnberichts
k.A.
| Gewinn per Aktie (EPS) | 8.36 |
| Bruttomarge | 35.98% |
| Nettogewinnspanne | 10.59% |
| Schulden/Eigenkapital-Verhältnis | 63.2% |
Wie hat sich CRL auf lange Sicht entwickelt?
Historische Performance und Vergleiche